Comparative Pharmacology
Head-to-head clinical analysis: CANTIL versus GLYCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANTIL versus GLYCORT.
CANTIL vs GLYCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CANTIL (mepenzolate bromide) is a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors, reducing gastrointestinal motility and gastric acid secretion.
Glucocorticoid receptor agonist; modulates gene expression to produce anti-inflammatory and immunosuppressive effects.
50 mg orally three times daily, may increase to 100 mg three times daily if needed
Intravenous: 2 mg/kg every 12 hours; Oral: 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours; clinically, this supports twice-daily dosing in patients with normal renal function.
3.5 hours (terminal); prolonged in hepatic impairment (up to 8 hours) and severe renal impairment (up to 6 hours)
Primarily renal excretion of unchanged drug and metabolites; approximately 60-70% eliminated renally, with about 30-40% excreted in feces via biliary elimination.
Renal: 70% as unchanged drug; biliary/fecal: 25% (metabolites); 5% other
Category C
Category C
Anticholinergic / Antispasmodic
Anticholinergic